Apotex Pty Ltd v Sanofi-Aventis Australia Pty Ltd (No 3)

Link copied
Case Copied 12 min read

FEDERAL COURT OF AUSTRALIA

Apotex Pty Ltd v Sanofi-Aventis Australia Pty Ltd (No 3) [2014] FCAFC 126

Citation: Apotex Pty Ltd v Sanofi-Aventis Australia Pty Ltd (No 3) [2014] FCAFC 126
Appeal from: Sanofi-Aventis Australia Pty Ltd v Apotex Pty Ltd (No 3) [2011] FCA 846
Parties: APOTEX PTY LTD (ACN 096 916 148) v SANOFI-AVENTIS AUSTRALIA PTY LTD
(ACN 008 558 807), SANOFI-AVENTIS DEUTSCHLAND GMBH and AVENTISUB II INCORPORATED
File number(s): NSD 2133 of 2011
Judge(s): BENNETT AND YATES JJ
Date of judgment: 26 September 2014
Catchwords: COSTS  – respondents successful at first instance and before the Full Court – appellant successful on infringement before the High Court – whether costs should follow the event or be assessed on an issues basis – percentage reduction of entitlement to costs  
Legislation: Australian Consumer Law 2011 (Cth), s 18
Therapeutic Goods Legislation Amendment (Copyright) Act 2011 (Cth)
Trade Practices Act 1974 (Cth), s 52
Cases cited: Apotex Pty Ltd v Sanofi-Aventis Australia Pty Ltd [2013] HCA 50
DSI Australia (Holdings) Pty Ltd v Garford Pty Ltd [2013] FCA 268
H Lundbeck A/S v Alphapharm Pty Ltd (No 2) [2009] FCAFC 118
PAC Mining Pty Ltd v Esco Corporation (No 2) [2009] FCAFC 52
Date of hearing: On the papers
Date of last submissions: 6 March 2014
Place: Sydney
Division: GENERAL DIVISION
Category: Catchwords
Number of paragraphs: 32
Counsel for the Appellant: D Catterns QC and N Murray
Solicitor for the Appellant: Herbert Smith Freehills
Counsel for the Respondents: R Cobden SC and C Dimitriadis
Solicitor for the Respondents: Jones Day

IN THE FEDERAL COURT OF AUSTRALIA

NEW SOUTH WALES DISTRICT REGISTRY

GENERAL DIVISION

NSD 2133 of 2011

ON APPEAL FROM THE FEDERAL COURT OF AUSTRALIA
BETWEEN:

APOTEX PTY LTD ACN 096 916 148
Appellant

AND:

SANOFI-AVENTIS AUSTRALIA PTY LTD
ACN 008 558 807
Respondent

JUDGES:

BENNETT AND YATES JJ

DATE OF ORDER:

26 SEPTEMBER 2014

WHERE MADE:

SYDNEY

THE COURT ORDERS THAT:

1.The respondents pay 60% of the appellant’s costs of the patent case at first instance.

2.The appellant pay the respondents’ costs of the copyright case at first instance, subject to a 20% reduction for the period between 29 July 2011 and 18 November 2011.

3.The respondents pay 70% of the appellant’s costs of the appeal.

4.The matter be remitted to a judge of the Federal Court for an inquiry as to the compensation payable on the respondents’ undertaking as to damages given to support the interlocutory injunction.

Note:    Entry of orders is dealt with in Rule 39.32 of the Federal Court Rules 2011.

IN THE FEDERAL COURT OF AUSTRALIA

NEW SOUTH WALES DISTRICT REGISTRY

GENERAL DIVISION

NSD 2133 of 2011

ON APPEAL FROM THE FEDERAL COURT OF AUSTRALIA
BETWEEN:

APOTEX PTY LTD ACN 096 916 148
Appellant

AND:

SANOFI-AVENTIS AUSTRALIA PTY LTD
ACN 008 558 807
Respondent

JUDGES:

BENNETT AND YATES JJ

DATE:

26 SEPTEMBER 2014

PLACE:

SYDNEY

REASONS FOR JUDGMENT

  1. After determination in the High Court (Apotex Pty Ltd v Sanofi-Aventis Australia Pty Ltd [2013] HCA…

CaseChat AU logo

Keep reading for free

Create a free CaseChat account to read Apotex Pty Ltd v Sanofi-Aventis Australia Pty Ltd (No 3) and more:

  • Read every judgment in full
  • Ask AI and get answers linked to paragraphs
  • See how each paragraph was cited in later cases
  • Download judgments as PDF or Word
Continue with Google

One click creates your free account or signs you in.

By continuing you agree to the Terms and Privacy Policy.

Details
Case
[2014] FCAFC 126
Decision Date

CaseChat Overview and Summary

Apotex Pty Ltd brought proceedings against Sanofi-Aventis Australia Pty Ltd in the Federal Court of Australia, alleging that Sanofi had infringed certain patents and copyright. Sanofi defended the action and cross-claimed for a declaration of non-infringement and invalidity of the patents and for a declaration that Apotex had not infringed Sanofi’s copyright. Apotex was successful in defending the patent infringement but unsuccessful in its cross-claim for invalidity. Sanofi was successful in defending the patent validity and in upholding the validity of the patents. Sanofi was also successful in the copyright infringement case. The parties appealed to the Full Court of the Federal Court, where Apotex was successful in its appeal on the question of patent infringement but Sanofi was successful in its appeal on the question of patent validity and in the copyright infringement case. The Full Court remitted the matter to the primary judge for determination of damages. Sanofi applied for an order for costs and Apotex cross-applied for costs. The court was required to determine the appropriate apportionment of costs between the parties for both the primary judge’s determination and the appeal to the Full Court.

The court considered the factors relevant to the broad discretion to award costs under section 43 of the Federal Court of Australia Act 1976 (Cth) in complex patent litigation such as this. The court noted that it was not uncommon for a party to cross-claim for revocation of a patent, but that such a claim may have costs consequences. The court distinguished between assertions of lack of novelty and obviousness, which could be considered discrete issues, and lack of fair basis, which may be ‘wrapped up’ in the arguments on construction. The court took into account that Apotex was ultimately successful in defending patent infringement but that its attack on the patent validity failed; Sanofi was successful in upholding patent validity in the face of the attack pressed in the appeal. Sanofi was successful in the copyright infringement case but that occupied a relatively small part of the appeal. The court considered that it was appropriate to make orders for the costs of the appeal compendiously, that is, of the patent case on infringement, the patent case on validity and the copyright infringement case.

Sanofi maintained its right to a separate order for the costs of the copyright claim but, in the alternative, set out its basis for apportionment. It submitted that any award of costs to Apotex for the appeal should be reduced by around 30%, to reflect the time taken for arguments on which Apotex failed. As to the trial, Sanofi submitted that a reduction of the order of 80% would be appropriate, but that this question should be remitted to the primary judge for determination. Sanofi pointed out that the time spent at trial was not all attributable to the patent case and said that the copyright case, on which it was successful, occupied at least 40% of the hearing time at trial and well in excess of 5% of the appeal. The court accepted Sanofi’s submissions and made orders for costs accordingly.

The court ordered that the respondents pay 60% of the appellant’s costs of the patent case at first instance. The court ordered that the appellant pay the respondents’ costs of the copyright case at first instance, subject to a 20% reduction for the period between 29 July 2011 and 18 November 2011. The court ordered that the respondents pay 70% of the appellant’s costs of the appeal. The court remitted the matter to a judge of the Federal Court for an inquiry as to the compensation payable on the respondents’ undertaking as to damages given to support the interlocutory injunction.

Orders

Orders of the court

1. The respondents pay 60% of the appellant’s costs of the patent case at first instance.

2. The appellant pay the respondents’ costs of the copyright case at first instance, subject to a 20% reduction for the period between 29 July 2011 and 18 November 2011.

3. The respondents pay 70% of the appellant’s costs of the appeal.

4. The matter be remitted to a judge of the Federal Court for an inquiry as to the compensation payable on the respondents’ undertaking as to damages given to support the interlocutory injunction.

Note: Entry of orders is dealt with in Rule 39.32 of the Federal Court Rules 2011.

Background

Background to the litigation

Evidence

Evidence Before The Court

Decision

Reasons for decision

Ratio Decidendi

Legal Principle Established

Sanofi maintains its right to a separate order for the costs of the copyright claim but, in the alternative, sets out its basis for apportionment. It submits that any award of costs to Apotex for the appeal should be reduced by around 30%, to reflect the time taken for arguments on which Apotex failed. As to the trial, Sanofi submits that a reduction of the order of 80% would be appropriate, but that this question should be remitted to the primary judge for determination. Sanofi points out that the time spent at trial was not all attributable to the patent case and says that the copyright case, on which it was successful, occupied at least 40% of the hearing time at trial and well in excess of 5% of the appeal. CONSIDERATION The factors relevant to the broad discretion to award costs under s 43 of the Federal Court of Australia Act 1976 (Cth) in complex patent litigation such as this have been referred to and summarised, for example, in PAC, H Lundbeck A/S v Alphapharm Pty Ltd (No 2) [2009] FCAFC 118 (Lundbeck) and DSI Australia (Holdings) Pty Ltd v Garford Pty Ltd [2013] FCA 268 (DSI). . Apotex says that the invalidity claim should be treated as a defensive claim against infringement. It is, of course, not uncommon for an allegedly infringing party to cross-claim for revocation. However, as explained in PAC, that may have costs consequences. In PAC, the Full Court discussed the competing factors where a party was successful in defending infringement but unsuccessful in a cross-claim for revocation of the patent. As their Honours said at [11], and is the case here, the respondent to the infringement action (here Apotex), could have successfully defended infringement without putting validity in issue. The claim for revocation was, their Honours observed, more than the presentation of conventional alternative defences to infringement, it was also a challenge to the validity of the patent. An unsuccessful attack entitled the patentee (here Sanofi), to obtain a certificate of validity. Their Honours were of the view that, in awarding costs, once a challenge is made both by way of defence and by way of attack, there is a case that has to be met. The Full Court distinguished between assertions of lack of novelty and obviousness on one hand, which could be considered discrete issues, and lack of fair basis which, may be ‘wrapped up’ in the arguments on construction. In DSI, Yates J took the view that the interplay in that case between claim infringement and claim invalidity by reason of construction was such that it was not possible to apportion costs on the basis of issues. This did not apply to manner of manufacture, sufficiency of description, best method or utility but, his Honour said, those issues occupied ‘minimal time’. These observations are apposite to this case.Costs of the appeal In our view, it is appropriate to make orders for the costs of the appeal compendiously, that is, of the patent case on infringement, the patent case on validity and the copyright infringement case. The question of construction was necessarily relevant to patent infringement and validity. We take into account that Apotex was ultimately successful in defending patent infringement but that its attack on the patent validity failed; Sanofi was successful in upholding patent validity in the face of the attack pressed in the appeal. Sanofi was successful in the copyright case but that occupied a relatively small part of the appeal.